Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review (Q36186039)

From Wikidata

Jump to navigation Jump to search

scientific article published in 2016

Language	Label	Description	Also known as
English	Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review	scientific article published in 2016

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

3 references

24 March 2019

25 April 2019

25 January 2021

Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review (English)

1 reference

Europe PubMed Central

12 August 2017

hyperprolactinemia

2 references

24 March 2019

25 April 2019

2 references

24 March 2019

25 April 2019

1 reference

25 January 2021

Kristian Thorlund

8

object named as

Kristian Thorlund

1 reference

Europe PubMed Central

12 August 2017

Edward J. Mills

7

object named as

Edward J Mills

1 reference

Europe PubMed Central

12 August 2017

author name string

Eric Druyts

1

1 reference

Europe PubMed Central

12 August 2017

Michael J Zoratti

2

1 reference

Europe PubMed Central

12 August 2017

Kabirraaj Toor

3

1 reference

Europe PubMed Central

12 August 2017

Ping Wu

4

1 reference

Europe PubMed Central

12 August 2017

Salmaan Kanji

5

1 reference

Europe PubMed Central

12 August 2017

Kiran Rabheru

6

1 reference

Europe PubMed Central

12 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 November 2016

4 references

Europe PubMed Central

12 August 2017

24 March 2019

25 April 2019

25 January 2021

4 references

Europe PubMed Central

12 August 2017

24 March 2019

25 April 2019

25 January 2021

16

1 reference

Europe PubMed Central

12 August 2017

181

1 reference

Europe PubMed Central

12 August 2017

1

1 reference

Europe PubMed Central

12 August 2017

copyright license

Creative Commons Attribution 4.0 International

3 references

Europe PubMed Central

24 March 2019

Europe PubMed Central

25 April 2019

Europe PubMed Central

25 January 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

https://scigraph.springernature.com/pub.10.1186/s12887-016-0710-y

0 references

The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Antipsychotic-induced hyperprolactinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

A roadmap to key pharmacologic principles in using antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

The effect of atypical antipsychotic agents on prolactin levels in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

2 July 2018

A study of serum prolactin levels in schizophrenia: comparison of males and females

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

2 July 2018

Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Ten years of antipsychotic prescribing to children: a Canadian population-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Prolactin levels during long-term risperidone treatment in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Serum prolactin levels in humans from birth to adult life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12887-016-0710-Y

1 reference

Europe PubMed Central

12 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36186039&oldid=1616305051"